GBA1 and Cognitive impairment: Patients with the G2019 variant of LRRK2 and PRKN mutations showed sustained advantages on motor complications and activities of daily living, whereas patients with GBA mutations frequently developed cognitive impairment and stimulation-resistant symptoms within 2 to 7 years after surgical treatment.